203,100 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 203,100 shares of the company’s stock, valued at approximately $3,973,000.

Other large investors also recently bought and sold shares of the company. KBC Group NV acquired a new stake in shares of Viridian Therapeutics during the first quarter valued at about $34,000. ANTIPODES PARTNERS Ltd acquired a new stake in Viridian Therapeutics in the 4th quarter valued at approximately $36,000. Larson Financial Group LLC acquired a new position in Viridian Therapeutics during the third quarter worth $52,000. US Bancorp DE boosted its position in shares of Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the period. Finally, State of Wyoming acquired a new stake in shares of Viridian Therapeutics in the first quarter valued at $93,000.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $23.59 on Friday. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -7.00 and a beta of 0.91. The firm’s fifty day simple moving average is $18.38 and its 200-day simple moving average is $21.67. Viridian Therapeutics, Inc. has a twelve month low of $13.18 and a twelve month high of $34.29. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 76.65%. The business had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.06 million. Equities analysts forecast that Viridian Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the acquisition, the director owned 5,090,928 shares in the company, valued at $86,545,776. The trade was a 30.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on VRDN shares. Wells Fargo & Company upgraded shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Viridian Therapeutics in a report on Monday, June 29th. Royal Bank Of Canada boosted their price target on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday. Truist Financial increased their price objective on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wall Street Zen cut Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $38.93.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.